- Report
- May 2024
- 134 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- May 2022
- 248 Pages
Global
From €2386EUR$2,500USD£1,999GBP
Epithelial Ovarian Cancer Drugs are a type of medication used to treat ovarian cancer. These drugs are designed to target the cancer cells and stop them from growing and spreading. They can be used alone or in combination with other treatments such as chemotherapy or radiation. Commonly used drugs include paclitaxel, carboplatin, and bevacizumab. These drugs work by blocking the growth of cancer cells, preventing them from spreading, and killing them.
Epithelial Ovarian Cancer Drugs are available in both generic and brand-name forms. Generic drugs are typically less expensive than brand-name drugs, but may not be as effective. Brand-name drugs are usually more expensive but may be more effective.
Some of the companies in the Epithelial Ovarian Cancer Drug market include Pfizer, Merck, Bristol-Myers Squibb, AstraZeneca, and Eli Lilly. Show Less Read more